GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
- 1 May 2005
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 288 (5) , G943-G949
- https://doi.org/10.1152/ajpgi.00303.2004
Abstract
Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone secreted in response to meal ingestion by enteroendocrine L cells located predominantly in the lower small intestine and large intestine. GLP-1 inhibits the secretion and motility of the upper gut and has been suggested to play a role in the “ileal brake.” In this study, we investigated the effect of recombinant GLP-1-(7–36) amide (rGLP-1) on lipid absorption in the small intestine in intestinal lymph duct-cannulated rats. In addition, the effects of rGLP-1 on intestinal production of apolipoprotein (apo) B and apo A-IV, two apolipoproteins closely related to lipid absorption, were evaluated. rGLP-1 was infused through the jugular vein, and lipids were infused simultaneously through a duodenal cannula. Our results showed that infusion of rGLP-1 at 20 pmol·kg−1·min−1 caused a dramatic and prompt decrease in lymph flow from 2.22 ± 0.15 (SE) ml/h at baseline (n = 6) to 1.24 ± 0.06 ml/h at 2 h (P < 0.001). In contrast, a significant increase in lymph flow was observed in the saline (control) group: 2.19 ± 0.20 and 3.48 ± 0.09 ml/h at baseline and at 6 h of lipid infusion, respectively (P < 0.001). rGLP-1 also inhibited intestinal triolein absorption (P < 0.05) and lymphatic apo B and apo A-IV output (P < 0.05) but did not affect cholesterol absorption. In conclusion, rGLP-1 dramatically decreases intestinal lymph flow and reduces triglyceride absorption and apo B and apo A-IV production. These findings suggest a novel role for GLP-1 in lipid absorption.Keywords
This publication has 46 references indexed in Scilit:
- Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Gut hormone PYY3-36 physiologically inhibits food intakeNature, 2002
- Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine TumorJournal of Clinical Endocrinology & Metabolism, 2002
- Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of DiabetesCurrent Pharmaceutical Design, 2001
- Glucagon-Like Peptide-1Recent Progress in Hormone Research, 2001
- Effects of glucagon-like peptide-1 (GLP-1) on glucose homeostasis and food intakeAppetite, 2000
- Effects of centrally or systemically injected glucagon-like peptide-1 (7–36) amide on release of neurohypophysial hormones and blood pressure in the ratRegulatory Peptides, 2000
- Effects of GLP-1 on Gastric Emptying, Antropyloric Motility, and Transpyloric Flow in Response to a Nonnutrient LiquidDigestive Diseases and Sciences, 1998
- Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.Journal of Clinical Investigation, 1994
- Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 1994